Marker Therapeutics Inc

MRKR11 Dec 2024
Healthcare
$3.86
+0.02 (+2.31%)
Lowest Today
$3.7
Highest Today
$4.19
Today’s Open
$3.86
Prev. Close
$3.89
52 Week High
$6.16
52 Week Low
$2.44
To Invest in Marker Therapeutics Inc

Marker Therapeutics Inc

Healthcare
MRKR11 Dec 2024
+0.02 (+2.31%)
1M
3M
6M
1Y
5Y
Low
$3.7
Day’s Range
High
$4.19
3.7
52 Week Low
$2.44
52-Week Range
52 Week High
$6.16
2.44
1 Day
-
1 Week
+11.78%
1 month return
+8.96%
3 month return
+43.01%
6 month return
+8.05%
1 Year return
-17.23%
3 Years return
-63.98%
5 Years return
-87.84%
10 Years return
-
Institutional Holdings
NEA Management Company, LLC
12.01
Aisling Capital Management LP
3.52
Vanguard Group Inc
2.72
Vanguard Total Stock Mkt Idx Inv
1.72
Vanguard Institutional Extnd Mkt Idx Tr
0.98
Geode Capital Management, LLC
0.8
Fidelity Extended Market Index
0.45

Market Status

Fundamentals
Market Cap
34.71 mln
PB Ratio
4.12
PE Ratio
0
Enterprise Value
12.57 mln
Total Assets
17.13 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Organisation
Marker Therapeutics Inc
Employees
8
Industry
Biotechnology
CEO
Dr. Juan F. Vera M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities